Somagenetix

Somagenetix is a biotech company about to enter the clinical stage with next-generation precision gene therapy. Co-founder Janine Reichenbach, chaired Professor for Somatic Gene Therapy at the University of Zurich, and her team, leverage 15 years of world-class scientific and clinical expertise to disrupt this market with a novel technology platform. Somagenetix has the potential to become a next-generation breakthrough technology and a global leader in the field of blood cell (phagocyte) disorders. Phagocytes that do not function or function falsely play a crucial role in more than 50 diseases, ranging from immunodeficiencies, neurodegenerative disorders to cancers. Somagenetix’s technology platform allows for cell-specific expression, i.e. activation of genes only in specific targets, in this case, phagocytes.
somagenetix logo
Founders / Management Jonathan Chriqui, Janine Reichenbach, Ulrich Wolfgang Siler
Sectors Biotech
Located in Zurich, Switzerland
Follow On

LinkedIn

I am text block. Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Sign up to receive our weekly newsletter and learn about investing in technologies that are changing the world.